| Kayla P Germano, PA-C | |
|
622 Bantam Rd, Bantam, CT 06750-1600 | |
| (860) 361-6650 | |
| (860) 361-6654 |
| Full Name | Kayla P Germano |
|---|---|
| Gender | Female |
| Speciality | Physician Assistant |
| Experience | 10 Years |
| Location | 622 Bantam Rd, Bantam, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801202072 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363A00000X | Physician Assistant | 3104 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Charlotte Hungerford Hospital | Torrington, CT | Hospital |
| Sharon Hospital | Sharon, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Litchfield County Orthopedic And Spine Pc | 5597941427 | 2 |
News Archive
A simple surface treatment technique demonstrated by a collaboration between researchers at the National Institute of Standards and Technology (NIST), Penn State and the University of Kentucky potentially offers a low-cost way to mass produce large arrays of organic electronic transistors on polymer sheets for a wide range of applications including flexible displays, "intelligent paper" and flexible sheets of biosensor arrays for field diagnostics.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
Research led by Warwick Medical School at the University of Warwick has found that Metformin, a drug treatment used to treat diabetes and also in women with Polycystic vary syndrome, may potentially provide protection against endometrial cancer.
Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal Antibody (RabMAb®) technology, today announced that the Company has signed a contract with SAIC Frederick, Inc., operating under contract with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer (CPTC) program (www.proteomics.cancer.gov).
A recently released paper published in the journal Alternatives to Laboratory Animals (ATLA 37, 399-416), presents a serious challenge to long-standing claims that animals are an important part of human cancer research.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kayla P Germano, PA-C 622 Bantam Rd, Bantam, CT 06750-1600 Ph: (860) 361-6650 | Kayla P Germano, PA-C 622 Bantam Rd, Bantam, CT 06750-1600 Ph: (860) 361-6650 |
News Archive
A simple surface treatment technique demonstrated by a collaboration between researchers at the National Institute of Standards and Technology (NIST), Penn State and the University of Kentucky potentially offers a low-cost way to mass produce large arrays of organic electronic transistors on polymer sheets for a wide range of applications including flexible displays, "intelligent paper" and flexible sheets of biosensor arrays for field diagnostics.
Michigan State University's new Goldwater Scholars for 2004 have a lot of work ahead of them – studying compounds shown to prevent cancer drug resistance and studying tomato genes and proteins.
Research led by Warwick Medical School at the University of Warwick has found that Metformin, a drug treatment used to treat diabetes and also in women with Polycystic vary syndrome, may potentially provide protection against endometrial cancer.
Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal Antibody (RabMAb®) technology, today announced that the Company has signed a contract with SAIC Frederick, Inc., operating under contract with the National Cancer Institute (NCI) of the U.S. National Institutes of Health (NIH) to develop several dozen rabbit monoclonal antibodies to support the Clinical Proteomic Technologies for Cancer (CPTC) program (www.proteomics.cancer.gov).
A recently released paper published in the journal Alternatives to Laboratory Animals (ATLA 37, 399-416), presents a serious challenge to long-standing claims that animals are an important part of human cancer research.
› Verified 7 days ago